ditional_info":null},{"id":30,"credit":6,"accreditation":{"id":3,"image":"https://imagedelivery.net/446RhcKSmHi3fzbXKA91IQ/934db6aa-0a7e-4c1b-741f-1934a1e36e00/public","title":"ABIM MOC II","description":"Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to {credit} Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit."},"activity_number":"0686-0000-25-039-L01-P","additional_info":null},{"id":31,"credit":6,"accreditation":{"id":4,"image":"https://imagedelivery.net/446RhcKSmHi3fzbXKA91IQ/4f570da2-09d4-45b7-2ba3-751609b94100/Icon","title":"ACPE Pharmacy","description":"$22"},"activity_number":"0686-0000-25-039-L01-P","additional_info":null}],"additional_tax":null,"exhibitor_link":"https://www.sponsorships.binaytara.org/ParkCityHeme","homepage_image":"https://imagedelivery.net/446RhcKSmHi3fzbXKA91IQ/fda05ae2-5d0a-4027-ee31-93e74dff6500/thumbnail","additional_info":null,"target_audience":"

This activity is intended for:

Practicing Medical Oncologists / Hematologists
Medical Oncology and Hematology Fellows
Oncology Nurses
Nurse Practitioners
Physician Assistants

ORGANIZING COMMITTEE:

Course Director:

Binay Shah, MD, MHA - Binaytara

Executive Chair:

Douglas Sborov, MD, MS - University of Utah Health

Planning Committee:
Bradley Hunter, MD - Intermountain Healthcare
Lindsey Fitzergald, MD, PhD - University of Utah Health
Xylina Gregg, MD - Utah Cancer Specialists

","meta_description":"","calculated_credit":null,"learning_objectives":"

Evaluate recent clinical trial data and updated guidelines to inform treatment decisions in newly diagnosed and relapsed multiple myeloma and lymphoma
Interpret the clinical relevance of novel mechanisms of action in emerging therapies for hematologic malignancies.
Integrate immunotherapies and targeted agents, including CAR T-cell therapy and bispecific antibodies, into individualized treatment plans.
Apply strategies for early identification and management of treatment-related toxicities.

","organizing_committee":null,"price_additional_info":null,"accreditation_additonal_info":"# Acknowledgement of Commercial Support\nThis activity is supported with an Independent Medical Education grant from Legend Biotech"},"programData":[{"id":1755553294328,"title":"Introductions","start":"2025-10-11T14:15:00.000Z","end":"2025-10-11T14:25:00.000Z","description":null,"raw_faculty":[{"id":333,"role":"conf_chair","uuid":"1ee8f439-8005-4994-87ef-b670daa55da0","conf_id":24,"faculty":{"id":1766,"bio":"$23","dob":null,"city":"Salt Lake City","uuid":"1ee8f439-8005-4994-87ef-b670daa55da0","email":"douglas.sborov@hci.utah.edu","state":"UT","prefix":"Dr.","street":"4626 S Idlewild Rd","country":"United States","zipcode":"84124","isActive":true,"latitude":null,"pronouns":null,"last_name":"Sborov","longitude":null,"time_zone":null,"work_city":null,"additional":null,"created_at":"2025-08-06T02:51:56.020123+00:00","first_name":"Douglas","npi_number":null,"updated_at":null,"work_state":nu

Conferences

Target Audience:

Learning Objectives: